Breast Cancer Foundation NZ
MSD MK-2870
Advanced Breast Cancer clinical trials for ER+
An open-label randomised Phase 3 study of MK - 2870 by itself and in combination with Keytruda versus a treatment of physicians choice in participants with HR+/HER2- unresectable, locally advanced or metastatic breast cancer.
Criteria
- Unresectable locally advanced or metastatic HR+/HER2- breast cancer.
- Disease recurrence on/after receiving a CDK4/6 inhibitor (eg palbociclib, ribociclib, abemaciclib).
- Patients who have had chemotherapy in metastatic setting are not eligible.
- Patients who have had disease recurrence within 6 months of completing adjuvant or neoadjuvant chemotherapy are not eligible.
New Zealand
Australia
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.